Feder Julie B reported grant involving 164,790 derivative units of Obsidian Therapeutics, Inc. at $0.00 for $0 on Aug 3, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Chief Financial Officer
Chief Financial Officer
Filed Nov 13, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
164,790Stock Option (Right to Buy)
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
164,790Direct
Trade date
Aug 3, 2026Grant
Filed
Nov 13, 2026, 4:58 PM ET102-day reporting delay
Accession
0001193125-26-460934Code A · Transaction 400995
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

Filing warnings

Notes recorded with this filing
1 warning
delayed filingThe filing was reported 102 calendar days after the transaction date.

OBX price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
OBX · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 20, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago1w ago1d ago
Returns since7d30d90d180d1y

Footnotes in full

F1: The shares underlying this option shall vest and become exercisable in sixteen (16) equal quarterly installments, with the first installment vesting on January 12, 2027, the second installment vesting on February 3, 2027, and the remaining installments vesting each quarter thereafter, subject to the Reporting Person's continued service with the Issuer on such vesting date.